Abstract

To investigate the efficacy and safety of bortezomib-dexamethasone,bortezomibmethylprednisolone combined with other drugs in the treatment of patients with multiple myeloma(MM).43 patients(male/female:32/9,mean age:58.13 years)with refractory or relapsed myeioma were treated.Other patients were administered bortezomib in combination with methylprednisolone or dexamethasone,or CPT and the common Toxicity Criteria,version 3.0(NCI,USA).The median follow-up fmm the start of bortezomib treatment was 9 months.Out of 43 refractory or relapsed patients,5 achieved CR,11 nearly CR,15 PR and 5 MR resulted in an ORR of 83.7%.The main toxicities were fatigue.gastrointestinal disorders.peripheral neuropathy,thrombocytopenia,herpes zoster,skin rash.All adverse effects were manageable with routine treatment.In short,Bortezomib plus other drugs is an very effective regiment,in which the side effects are predictable and manageable. Key words: Multiple myeloma; Refractory or relapsed; Bortezomib; Antineoplastic combined chemotherapy protocols

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.